研究单位：[1]Beijing Tongren Hospital, CMU,Beijing,China[2]Keymed Biosciences Co.Ltd[3]Beijing Chaoyang Hospital, CMU,Beijing,China[4]Beijing Hospital,Beijing,China[5]Beijing Renmin Hospital,Beijing,China[6]Zhejiang Provincial People's Hospital,Hangzhou,Zhejiang,China[7]First Affiliated Hospital of Chongqing Medical University,Chongqing,Chongqing,China[8]Jingzhou Central Hospital,Jingzhou,Hubei,China[9]Renmin Hospital of Wuhan University,Wuhan,Hubei,China[10]Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology,Wuhan,Hubei,China[11]Third Xiangya Hospital of Central South University,Changsha,Hunan,China[12]The First Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China[13]Affiliated Hospital of Qingdao University,Qingdao,Shandong,China[14]Yantai Yuhuangding Hospital,Yantai,Shandong,China[15]Shandong Second Provincial General Hospital (Shandong ENT hospital),Jinan,Shangdong,China[16]Renji Hospital of Shanghai Jiaotong University School of Medicine,Shanghai,Shanghai,China[17]Tongji Hospital of Tongji University,Shanghai,Shanghai,China[18]Second Hospital of Shanxi Medical University,Taiyuan,Shanxi,China[19]Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu,Sichuan,China[20]West China Hospital of Sichuan University,Chengdu,Sichuan,China
This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy, safety, PK, PD and immumogenicity of CM310 in comparison to placebo in addition to a background treatment of mometasone furcate nasal spray (MFNS) in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP).
